RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second-Chance CAR-T: could Off-Spec cells still fight cancer?
Disease control Recruiting nowThis phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial is testing a CAR-T cell therapy made using an automated process for people with relapsed or refractory large B-cell lymphoma. The study will enroll 12 adults whose cancer has not responded to or returned after first-line treatment. Researchers will measure …
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to supercharge CAR T-Cells against tough lymphoma
Disease control Recruiting nowThis early-phase trial tests whether adding a drug called NT-I7 after standard CAR T-cell therapy can help the immune cells work better and last longer in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after their CAR T treatmen…
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The …
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Affordable CAR-T breakthrough: academic therapy offers new hope for blood cancer patients
Disease control Recruiting nowThis study is testing a more affordable version of CAR-T cell therapy for people with relapsed or hard-to-treat large B-cell lymphoma. The treatment uses the patient's own immune cells, modified to attack cancer cells. The goal is to see if this academic-made therapy works as wel…
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Recruiting nowThis phase 2 study is testing whether combining two drugs—epcoritamab and loncastuximab tesirine—can safely shrink or eliminate lymphoma in people whose large B-cell lymphoma has come back or not responded to treatment. About 26 adults will receive the drugs over several cycles. …
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New Dual-Target CAR-T therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The goal is to find the saf…
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Scientists hunt for clues to predict CAR-T success in hard-to-treat lymphoma
Knowledge-focused Recruiting nowThis study aims to find out which factors help predict whether CAR-T therapy will work in people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better…
Matched conditions: RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC